Heike Schäcke

Summary

Affiliation: Schering AG
Country: Germany

Publications

  1. ncbi request reprint Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index
    Heike Schäcke
    Bayer Schering Pharma AG, Global Drug Discovery, TRG Inflammation Immunology, Müllerstr 178, 13342 Berlin, Germany
    Mol Cell Endocrinol 275:109-17. 2007
  2. pmc Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
    Heike Schäcke
    Corporate Research Business Area Dermatology, Corporate Project Management Strategic Business Unit Specialized Therapeutics, and Medicinal Chemistry, Schering AG, Berlin, D 13342 Berlin, Germany
    Proc Natl Acad Sci U S A 101:227-32. 2004
  3. ncbi request reprint Dissociated glucocorticoid receptor ligands
    Heike Schäcke
    Schering AG, Corporate Research, Mullerstrasse 178, 13342 Berlin, Germany
    Curr Opin Investig Drugs 5:524-8. 2004
  4. ncbi request reprint Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index
    Heike Schäcke
    Schering AG, RBA Dermatology Europe, 13342 Berlin, Germany
    Curr Opin Investig Drugs 6:503-7. 2005
  5. ncbi request reprint Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
    Heike Schäcke
    CRBA Inflammation, Corporate Research, Schering AG, Berlin, Germany
    Exp Dermatol 15:565-73. 2006
  6. ncbi request reprint Glucocorticoid therapy-induced skin atrophy
    Stefanie Schoepe
    Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
    Exp Dermatol 15:406-20. 2006
  7. ncbi request reprint Mechanisms involved in the side effects of glucocorticoids
    Heike Schäcke
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Pharmacol Ther 96:23-43. 2002
  8. ncbi request reprint Dichotomy of glucocorticoid action in the immune system
    Khusru Asadullah
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Trends Immunol 23:120-2. 2002
  9. ncbi request reprint GR ligands: can we improve the established drugs?
    Hartmut Rehwinkel
    Schering AG, Corporate Research, Medicinal Chemistry, 13342 Berlin, Germany
    ChemMedChem 1:803-5. 2006
  10. doi request reprint Discovery of quinolines as selective glucocorticoid receptor agonists
    Stefan Jaroch
    Medicinal Chemistry Berlin, Lead Generation and Optimization, Bayer Schering Pharma AG, Berlin D 13342, Germany
    Bioorg Med Chem Lett 20:5835-8. 2010

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index
    Heike Schäcke
    Bayer Schering Pharma AG, Global Drug Discovery, TRG Inflammation Immunology, Müllerstr 178, 13342 Berlin, Germany
    Mol Cell Endocrinol 275:109-17. 2007
    ..Such selective GR agonists (SEGRAs) are likely to enter clinical testing soon...
  2. pmc Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
    Heike Schäcke
    Corporate Research Business Area Dermatology, Corporate Project Management Strategic Business Unit Specialized Therapeutics, and Medicinal Chemistry, Schering AG, Berlin, D 13342 Berlin, Germany
    Proc Natl Acad Sci U S A 101:227-32. 2004
    ..Moreover, they are useful tool compounds for further investigating the mechanisms of GR-mediated effects...
  3. ncbi request reprint Dissociated glucocorticoid receptor ligands
    Heike Schäcke
    Schering AG, Corporate Research, Mullerstrasse 178, 13342 Berlin, Germany
    Curr Opin Investig Drugs 5:524-8. 2004
    ..Several pharmaceutical companies are currently pursuing this goal...
  4. ncbi request reprint Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index
    Heike Schäcke
    Schering AG, RBA Dermatology Europe, 13342 Berlin, Germany
    Curr Opin Investig Drugs 6:503-7. 2005
    ..Compounds that preferentially induce transrepression rather than transactivation should be superior to classical glucocorticoids. Indeed, proof of concept has been recently achieved with such selective glucocorticoid receptor agonists...
  5. ncbi request reprint Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
    Heike Schäcke
    CRBA Inflammation, Corporate Research, Schering AG, Berlin, Germany
    Exp Dermatol 15:565-73. 2006
    ..Nevertheless, considerable improvement in the therapeutic action of glucocorticoid receptor ligands is being achieved through the use of key molecular targets for screening novel glucocorticoid receptor ligands...
  6. ncbi request reprint Glucocorticoid therapy-induced skin atrophy
    Stefanie Schoepe
    Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
    Exp Dermatol 15:406-20. 2006
    ..New insights into GC modes of action will guide optimization strategies aiming at novel GC receptor ligands with improved effect/side effect profile...
  7. ncbi request reprint Mechanisms involved in the side effects of glucocorticoids
    Heike Schäcke
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Pharmacol Ther 96:23-43. 2002
    ..The focus on the molecular aspects should be helpful in predicting the potential advantages of selective GR agonists in comparison to classical GCs...
  8. ncbi request reprint Dichotomy of glucocorticoid action in the immune system
    Khusru Asadullah
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Trends Immunol 23:120-2. 2002
  9. ncbi request reprint GR ligands: can we improve the established drugs?
    Hartmut Rehwinkel
    Schering AG, Corporate Research, Medicinal Chemistry, 13342 Berlin, Germany
    ChemMedChem 1:803-5. 2006
  10. doi request reprint Discovery of quinolines as selective glucocorticoid receptor agonists
    Stefan Jaroch
    Medicinal Chemistry Berlin, Lead Generation and Optimization, Bayer Schering Pharma AG, Berlin D 13342, Germany
    Bioorg Med Chem Lett 20:5835-8. 2010
    ..Compounds were shown to be efficacious in cell assays with respect to inflammation endpoints, along with reduced activity in a transactivation assay, hinting at an improved therapeutic window over corticosteroids...
  11. ncbi request reprint Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty
    Uwe Pleyer
    Department of Ophthalmology, Institute of Pharmacy, Charite, Humboldt University, Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 243:450-5. 2005
    ..We set out to evaluate the effect of a SEGRA compound following topical application on the course of experimental orthotopic corneal grafts...
  12. doi request reprint Shortened treatment duration of glucocorticoid-induced skin atrophy in rats
    Stefanie Schoepe
    Exp Dermatol 20:853-5. 2011
    ..We show here that the treatment duration of rat skin atrophy models might be reduced to 5 days for economical and ethical reasons...